Teflaro : Teflaro® (ceftaroline fosamil) for injection

2.33 Rating by ClearWebStats

teflaro.com is 1 decade 5 years 8 months old. This website has a #15,521,915 rank in global traffic. It has a com as an domain extension. This website has a Google PageRank of 4 out of 10. The DNS for Teflaro is hosted at 208.97.227.209. While no active threats were reported recently by users, teflaro.com is SAFE to browse.

Updated 1 decade 1 year ago

Get Custom Widget

Traffic Report of Teflaro

Daily Unique Visitors:	31
Daily Pageviews:	62

Estimated Valuation

Income Per Day:	$ 0.15
Estimated Worth:	$ 8.95

Search Engine Indexes

Google Indexed Pages:	Not Applicable
Yahoo Indexed Pages:	Not Applicable
Bing Indexed Pages:	3

Search Engine Backlinks

Google Backlinks:	Not Applicable
Bing Backlinks:	4

Safety Information

Google Safe Browsing:	No Risk Issues
Siteadvisor Rating:	Not Applicable
WOT Trustworthiness:	Not Applicable
WOT Privacy:	Not Applicable
WOT Child Safety:	Not Applicable

Website Ranks & Scores

Google Pagerank:
Alexa Rank:	15,521,915
Domain Authority:	Not Applicable

Google Pagerank

PR 4 out of 10

PageSpeed Score

Score: 81on 100

Siteadvisor Rating

Not Applicable

Where is teflaro.com server located?

Hosted IP Address:

208.97.227.209

Hosted Country:

Location Latitude:

40.1215

Location Longitude:

-75.3399

Social Engagement

Facebook Shares:	16
Facebook Likes:	Not Applicable
Facebook Comments:	2

Page Resources Breakdown

Homepage Links Analysis

Teflaro® (ceftaroline fosamil) for injection – Official Site

Learn more about Teflaro treatment and find the important safety information. Teflaro is an IV cephalosporin for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible pathogens. TEFLARO is indicated for the treatment of community-acquired bacterial pneumonia (CABP) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: Streptococcus pneumoniae (including cases with concurrent bacteremia), Staphylococcus aureus (methicillin-susceptible isolates only), Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli. TEFLARO is also indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca. To reduce the development of drug-resistant bacteria and maintain the effectiveness of TEFLARO and other antibacterial drugs, TEFLARO should be used to treat only ABSSSI or CABP that are proven or strongly suspected to be caused by susceptible bacteria. Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to ceftaroline. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. TEFLARO is contraindicated in patients with known serious hypersensitivity to ceftaroline or other members of the cephalosporin class. Anaphylaxis and anaphylactoid reactions have been reported with ceftaroline. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported with beta-lactam antibacterials. Before therapy with TEFLARO is instituted, careful inquiry about previous hypersensitivity reactions to other cephalosporins, penicillins, or carbapenems should be made. If this product is to be given to a penicillin- or other beta-lactam-allergic patient, caution should be exercised because cross sensitivity among beta-lactam antibacterial agents has been clearly established. If an allergic reaction to TEFLARO occurs, the drug should be discontinued. Serious acute hypersensitivity (anaphylactic) reactions require emergency treatment with epinephrine and other emergency measures that may include airway management, oxygen, intravenous fluids, antihistamines, corticosteroids, and vasopressors as clinically indicated. Clostridium difficile-associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including TEFLARO, and may range in severity from mild diarrhea to fatal colitis. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents. If CDAD is suspected or confirmed, antibacterials not directed against C. difficile should be discontinued, if possible. Seroconversion from a negative to a positive direct Coombs’ test result occurred in 120/1114 (10.8%) of patients receiving TEFLARO and 49/1116 (4.4%) of patients receiving comparator drugs in the four pooled Phase 3 trials. No adverse reactions representing hemolytic anemia were reported in any treatment group. If anemia develops during or after treatment with TEFLARO, drug-induced hemolytic anemia should be considered. If drug-induced hemolytic anemia is suspected, discontinuation of TEFLARO should be considered and supportive care should be administered to the patient if clinically indicated. Prescribing TEFLARO in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. In the four pooled Phase 3 clinical trials, serious adverse events occurred in 98/1300 (7.5%) of patients receiving TEFLARO and 100/1297 (7.7%) of patients receiving comparator drugs. Treatment discontinuation due to adverse events occurred in 35/1300 (2.7%) of patients receiving TEFLARO and 48/1297 (3.7%) of patients receiving comparator drugs with the most common adverse events leading to discontinuation being hypersensitivity for both treatment groups at a rate of 0.3% in the TEFLARO group and 0.5% in the comparator group. No adverse reactions occurred in greater than 5% of patients receiving TEFLARO. The most common adverse reactions occurring in >2% of patients receiving TEFLARO in the pooled Phase 3 clinical trials were diarrhea, nausea, and rash. No clinical drug-drug interaction studies have been conducted with TEFLARO. There is minimal potential for drug-drug interactions between TEFLARO and CYP450 substrates, inhibitors, or inducers; drugs known to undergo active renal secretion; and drugs that may alter renal blood flow. TEFLARO has not been studied in pregnant women. Therefore, TEFLARO should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. It is not known whether ceftaroline is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TEFLARO is administered to a nursing woman. Safety and effectiveness in pediatric patients have not been established. Because elderly patients, those ≥65 years of age, are more likely to have decreased renal function and ceftaroline is excreted primarily by the kidney, care should be taken in dose selection in this age group and it may be useful to monitor renal function. Dosage adjustment for elderly patients should therefore be based on renal function. Dosage adjustment is required in patients with moderate (CrCl >30 to ≤50 mL/min) or severe (CrCl ≥15 to ≤30 mL/min) renal impairment and in patients with end-stage renal disease (CrCl

teflaro, teflaro treatment, treating cabp, treating absssi, ceftaroline fosamil, cabp, absssi

Similar Domain Names

These are similar domain names that may be used for typosquatting or phishing attacks. Always verify the URL before entering any sensitive information.

teflaro.co
teflaro.cm
teflaro.con
teflaro.net
teflaro.org
tteflaro.com
teeflaro.com
tefflaro.com
tefllaro.com
teflaaro.com
teflarro.com
teflaroo.com
eflaro.com
tflaro.com
telaro.com

Website Inpage Analysis

H1 Headings:	6	H2 Headings:	4
H3 Headings:	Not Applicable	H4 Headings:	Not Applicable
H5 Headings:	2	H6 Headings:	9
Total IFRAMEs:	Not Applicable	Total Images:	6
Google Adsense:	Not Applicable	Google Analytics:	Not Applicable

Websites Hosted on Same IP (i.e. 208.97.227.209)

A Growing Pharmaceutical Company

- frx.com

314,936

$ 16,200.00

Namenda (memantine HCl) â Taking Namenda

- namenda.com

Namenda (memantine HCl) - Learn more about Namenda and find information for patients and caregivers including Namenda side effects, treatments, indications, FAQs and resources. Namenda (memantine HCl) is indicated for the treatment of moderate to severe Alzheimerâs disease. Namenda is available by prescription only. Namenda should not be taken by anyone who is allergic to Namenda or has had a bad reaction to Namenda or any of its components....

2,399,733

$ 240.00

Anti-Static Valved Holding Chamber | AeroChamber Plus® Flow-Vu® (aVHC)

- aerochambervhc.com

The AeroChamber Plus Flow-Vu (aVHC) is a prescription only Anti-Static Valved Holding Chamber for patients who require assistance with the proper use of Metered Dose Inhalers in the delivery of medication.

5,089,354

$ 240.00

Treatment for Patients with Moderate to Severe Alzheimer’s Disease

- namendaxrhcp.com

Safety and prescribing information for NAMENDA XR® (memantine HCI), a once-daily treatment for moderate to severe dementia of the Alzheimer’s type.

7,479,789

$ 8.95

Forest Laboratories Prescription Products

- lexapro.com

Not Applicable

$ 8.95

HTTP Header Analysis

Http-Version: 1.1
Status-Code: 200
Status: 200 OK
Cache-Control: private
Content-Type: text/html; charset=utf-8
Content-Encoding: gzip
Vary: Accept-Encoding
Server: Microsoft-IIS/7.5
X-AspNet-Version: 2.0.50727
X-Powered-By: ASP.NET
Date: Fri, 13 Jun 2014 09:51:10 GMT
Content-Length: 13199

Domain Information for teflaro.com

Domain Registrar:	ENOM, INC.
Registration Date:	2010-06-22 1 decade 5 years 8 months ago
Last Modified:	2011-03-08 1 decade 4 years 11 months ago
Expiration Date:	2020-06-22 5 years 8 months 6 days ago
Domain Status:	clientTransferProhibited

Domain Nameserver Information

Host	IP Address	Country
ns1.frx.com	69.27.233.247	United States
ns2.frx.com	63.76.230.145	United States
ns3.frx.com	65.69.34.3	United States
ns4.frx.com	69.45.100.149	United States

DNS Record Analysis

Host	Type	TTL	Extra
teflaro.com	A	86400	IP:208.97.227.209
teflaro.com	NS	86400	Target:ns3.frx.com
teflaro.com	NS	86400	Target:ns1.frx.com
teflaro.com	NS	86400	Target:ns2.frx.com
teflaro.com	NS	86400	Target:ns4.frx.com
teflaro.com	SOA	900	MNAME:ns1.frx.com RNAME:hostmaster.frx.com Serial:19 Refresh:1800 Retry:300 Expire:2592000 Minimum TTL:900